461 related articles for article (PubMed ID: 25933799)
1. Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.
Lenders M; Stypmann J; Duning T; Schmitz B; Brand SM; Brand E
J Am Soc Nephrol; 2016 Jan; 27(1):256-64. PubMed ID: 25933799
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
3. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
4. Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up study.
Schiffmann R; Pastores GM; Lien YH; Castaneda V; Chang P; Martin R; Wijatyk A
Orphanet J Rare Dis; 2014 Nov; 9():169. PubMed ID: 25425121
[TBL] [Abstract][Full Text] [Related]
5. Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Lenders M; Canaan-Kühl S; Krämer J; Duning T; Reiermann S; Sommer C; Stypmann J; Blaschke D; Üçeyler N; Hense HW; Brand SM; Wanner C; Weidemann F; Brand E
J Am Soc Nephrol; 2016 Mar; 27(3):952-62. PubMed ID: 26185201
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
Goláň L; Goker-Alpan O; Holida M; Kantola I; Klopotowski M; Kuusisto J; Linhart A; Musial J; Nicholls K; Gonzalez-Rodriguez D; Sharma R; Vujkovac B; Chang P; Wijatyk A
Drug Des Devel Ther; 2015; 9():3435-44. PubMed ID: 26185417
[TBL] [Abstract][Full Text] [Related]
7. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
8. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
9. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial.
Ramaswami U; Bichet DG; Clarke LA; Dostalova G; Fainboim A; Fellgiebel A; Forcelini CM; An Haack K; Hopkin RJ; Mauer M; Najafian B; Scott CR; Shankar SP; Thurberg BL; Tøndel C; Tylki-Szymanska A; Bénichou B; Wijburg FA
Mol Genet Metab; 2019 May; 127(1):86-94. PubMed ID: 30987917
[TBL] [Abstract][Full Text] [Related]
10. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study.
Arends M; Biegstraaten M; Wanner C; Sirrs S; Mehta A; Elliott PM; Oder D; Watkinson OT; Bichet DG; Khan A; Iwanochko M; Vaz FM; van Kuilenburg ABP; West ML; Hughes DA; Hollak CEM
J Med Genet; 2018 May; 55(5):351-358. PubMed ID: 29437868
[TBL] [Abstract][Full Text] [Related]
11. Update on role of agalsidase alfa in management of Fabry disease.
Ramaswami U
Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
[TBL] [Abstract][Full Text] [Related]
12. Effects of Baseline Left Ventricular Hypertrophy and Decreased Renal Function on Cardiovascular and Renal Outcomes in Patients with Fabry Disease Treated with Agalsidase Alfa: A Fabry Outcome Survey Study.
Feriozzi S; Linhart A; Ramaswami U; Kalampoki V; Gurevich A; Hughes D;
Clin Ther; 2020 Dec; 42(12):2321-2330.e0. PubMed ID: 33218740
[TBL] [Abstract][Full Text] [Related]
13. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.
Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F
Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505
[TBL] [Abstract][Full Text] [Related]
14. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease.
Fellgiebel A; Gartenschläger M; Wildberger K; Scheurich A; Desnick RJ; Sims K
Cerebrovasc Dis; 2014; 38(6):448-56. PubMed ID: 25502511
[TBL] [Abstract][Full Text] [Related]
16. Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome.
Rombach SM; Aerts JM; Poorthuis BJ; Groener JE; Donker-Koopman W; Hendriks E; Mirzaian M; Kuiper S; Wijburg FA; Hollak CE; Linthorst GE
PLoS One; 2012; 7(10):e47805. PubMed ID: 23094092
[TBL] [Abstract][Full Text] [Related]
17. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.
Ripeau D; Amartino H; Cedrolla M; Urtiaga L; Urdaneta B; Cano M; Valdez R; Antongiovanni N; Masllorens F
Medicina (B Aires); 2017; 77(3):173-179. PubMed ID: 28643672
[TBL] [Abstract][Full Text] [Related]
18. Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY.
Mauhin W; Lidove O; Amelin D; Lamari F; Caillaud C; Mingozzi F; Dzangué-Tchoupou G; Arouche-Delaperche L; Douillard C; Dussol B; Leguy-Seguin V; D'Halluin P; Noel E; Zenone T; Matignon M; Maillot F; Ly KH; Besson G; Willems M; Labombarda F; Masseau A; Lavigne C; Froissart R; Lacombe D; Ziza JM; Hachulla E; Benveniste O
Orphanet J Rare Dis; 2018 Jul; 13(1):127. PubMed ID: 30064518
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg.
Vedder AC; Linthorst GE; Houge G; Groener JE; Ormel EE; Bouma BJ; Aerts JM; Hirth A; Hollak CE
PLoS One; 2007 Jul; 2(7):e598. PubMed ID: 17622343
[TBL] [Abstract][Full Text] [Related]
20. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.
Weidemann F; Krämer J; Duning T; Lenders M; Canaan-Kühl S; Krebs A; Guerrero González H; Sommer C; Üçeyler N; Niemann M; Störk S; Schelleckes M; Reiermann S; Stypmann J; Brand SM; Wanner C; Brand E
J Am Soc Nephrol; 2014 Apr; 25(4):837-49. PubMed ID: 24556354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]